The oral antiviral drug, which is a combination of nirmatrelvir and ritonavir tablets, "is the best therapeutic choice for high-risk patients to date", according to the global health body.
The results suggest a sub-group of patients who would likely benefit from this therapy, and they highlight the need for additional studies in the development of this therapy.
Pfizer will not receive royalties on sales in low-income countries and will further waive royalties on sales in all countries covered by the agreement while Covid-19 remains classified as a Public Health Emergency of International Concern by the World Health Organization.
Copyright © 2024 - Odisha Television Limited All Rights Reserved.